From orbit to cortex: recognising teprotumumab-induced encephalopathy.

Autoimmune-related adverse effects may occur from monoclonal antibody medications though autoimmune encephalopathy is not a commonly reported reaction. Inhibiting the insulin-like growth factor 1 pathway has been shown to cause neurocognitive side effects. We report a case of a man in his early 60s who presented with neuropsychiatric changes after beginning teprotumumab for thyroid eye disease. He was diagnosed with teprotumumab-induced encephalopathy and ultimately treated with plasma exchange.